Welcome to the OncoSil Medical Ltd investor centre
OncoSil Medical Ltd is a publicly traded biotechnology company on the Australian stock exchange (ASX: OSL).
Our mission is to transform the prognosis for people with pancreatic cancer. We believe it’s time to change the conversation around cancers with poor prognoses and transform the approach to cancer treatment. OncoSilTM is our breakthrough† brachytherapy device.1,2
At OncoSil Medical we have a policy of continuous disclosure. We keep shareholders informed through ASX announcements, the company website, regular newsletters and our annual report. We encourage our shareholders to attend and participate at our annual general meetings.
†OncoSil™ has received breakthrough device designation in the European Union, United Kingdom and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy.1,2
REFERENCES: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. 2. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.
Contacts for shareholders
You can access current holding and dividend information and update personal information, such as address and direct credit details, via our share registry, InvestorServe.